Unicycive Therapeutics Completes The UNI-494 Phase 1 Study In Healthy Volunteers, These Results Will Help Determine The Dose And Schedule Of UNI-494 For A Potential Phase 2 Trial In Patients With Acute Kidney Injury
Unicycive Therapeutics Completes The UNI-494 Phase 1 Study In Healthy Volunteers, These Results Will Help Determine The Dose And Schedule Of UNI-494 For A Potential Phase 2 Trial In Patients With Acute Kidney Injury
Unicycive Therapeutics完成了在健康志願者中進行的UNI-494第一階段研究，這些結果將有助於判斷UNI-494的劑量和計劃，用於潛在的第二階段試驗，針對急性腎損傷患者。
Unicycive Therapeutics Completes The UNI-494 Phase 1 Study In Healthy Volunteers, These Results Will Help Determine The Dose And Schedule Of UNI-494 For A Potential Phase 2 Trial In Patients With Acute Kidney Injury
Unicycive Therapeutics完成了在健康志願者中進行的UNI-494第一階段研究，這些結果將有助於判斷UNI-494的劑量和計劃，用於潛在的第二階段試驗，針對急性腎損傷患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間